. 2020 Jun 24;8(3):342–359. doi: 10.1002/iid3.315

Table 1.

BORTEM‐17 patient characteristics

Patient ID	Age	Sex	MGMT status	% of methylation (pyrosequence) mean ± SEM	KPS	Molecular pathology				No. of recurrence before recruitment	Treatment after recurrence before recruitment	Treatment after withdrawn	No. of BORTEM cycle after recruitment	OS, mo	Survival after first recurrence	Survival after 2nd recurrence	Survival after recruitment
Patient ID	Age	Sex	MGMT status	% of methylation (pyrosequence) mean ± SEM	KPS	KIR2DS4	IDH1	ATRX	TP53	No. of recurrence before recruitment	Treatment after recurrence before recruitment	Treatment after withdrawn	No. of BORTEM cycle after recruitment	OS, mo	Survival after first recurrence	Survival after 2nd recurrence	Survival after recruitment
P01	45	M	UM	3 ± 1.1	90	Func/Del	Mut	Mut	Mut	2	SRS + TMZ	LAVA	3	27.3	13.4	7.1	6.6
P02	53	F	UM	2 ± 0.6	80	Func/Func	Wt	Wt	n/a	2	S + SRS	No antineoplastic treatment	2	24.0	9.6	6.7	6.2
P03	54	M	UM	2 ± 0.6	80	Del/Del	Wt	n/a	n/a	2	TMZ	Lomustin + RT	6	33.8	18.6	15.2	14.5
P04	40	F	UM	3 ± 1.7	90	Del/Del	Mut	Wt	Wt	1	No antineoplastic treatment	No antineoplastic treatment	2	13.8	4.7	2.1	3.8
P05 ^a	35	M	UM	2 ± 0.3	90	Del/Del	Mut	Mut	Mut	2	S	LAVA	2	30.6	25.0	14.7	14.4
P06	35	F	UM	3 ± 0.7	90	Func/Func	Wt	Wt	Wt	2	SRS	SRS	2	15.2	6.1	4.9	3.2
P07 ^a	26	M	UM	1 ± 0.2	100	Del/Del	Mut	Mut	Wt	1	No antineoplastic treatment	LAVA	2	28.0	11.3	8.9	10.6
P08	57	M	UM	2 ± 0.4	80	Func/Del	Wt	Wt	n/a	1	No antineoplastic treatment	LAVA	2	18.7	4.6	2.3	4.2
P09	58	M	UM	2 ± 0.8	90	Del/Del	Wt	n/a	n/a	2	SRS	No antineoplastic treatment	2	12.8	3.9	2.6	2.2
P10	52	M	UM	4 ± 1.3	80	Func/Del	Wt	n/a	n/a	2	S	No antineoplastic treatment	2	11.2	6.4	3.3	2.4
Median survival, mo														21.4	8.0	5.8	5.2

Abbreviations: ATRX, α‐thalassemia/mental retardation, X‐linked; BORTEM‐17, bortezomib and temozolomide trial 2017; Del, KIR2DS4*00101 deleted (Del/Del homozygous); F, female; Func, KIR2DS4*00101 full length (Func/Func homozygous, Func/Del heterozygous); IDH1, isocitrate dehydrogenase‐1; KIR2DS4, killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4; KPS, Karnofsky performance status; LAVA, combination of lomustine, avastin and vincristine; M, male; Mut, mutated; n/a, not available; OS, (overall survival in months) from date of first operation; RT, radiotherapy; S, surgery; SRS, stereotactic radio surgery; Survival after first recurrence, survival after date of MRI showing 1st progression; Survival after recruitment, survival after date of recruitment to last date of update; Survival after second recurrence, survival after date of MRI showing 2nd progression; TMZ, temozolomide; TP53, tumour protein 53; UM MGMT, unmethylated O⁶ methylguanine DNA methyltransferase; Wt, wild type.

^{^a}

Alive.